Boston Scientific (BSX) reported Q2 adjusted earnings Wednesday of $0.75 per diluted share, up from $0.62 a year earlier.
Analysts polled by FactSet expected $0.73.
Net sales for the quarter ended June 30 were $5.06 billion compared with $4.12 billion a year earlier.
Analysts surveyed by FactSet expected $4.89 billion.
For Q3, the company expects adjusted EPS of $0.70 to $0.72. Analysts are looking for $0.70.
Net sales for the quarter are projected to rise 17% to 19%, according to the company.
For 2025, Boston Scientific said it now expects adjusted EPS of $2.95 to $2.99 versus its prior outlook range of $2.87 to $2.94. Analysts are looking for $2.92.
The company now projects full-year net sales growth at 18% to 19% versus its previous guidance range of 15% to 17%.
Boston Scientific shares were up 1% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.